[Anti-herpes simplex virus action of combined therapy with cyclocytidine and ganciclovir].
The study was designed to investigate the combined effect of cyclocytidine (CC) and ganciclovir (GCV) on herpes simplex virus-1 (HSV-1) in cell culture. The 50% inhibition concentrations of HSV-1 plaque formation (IC50) of CC, GCV alone and in combination were determined by the inhibitory test of plaque formation. The combined anti-HSV-1 effect of CC and GCV was evaluated by a graphic method and fractional inhibitory concentration (FIC) indexes. IC50 of CC and GCV was 0.19 and 0.1 micrograms/ml, respectively. The combination of CC with GCV produced significantly synergistic activity against HSV-1 in cell culture. FIC indexes were all below 0.75. The combined therapy of CC and GCV can also decrease and delay the emergence of drug-resistant variants. These results suggest that this combined therapy of CC and GCV may be a potentially effective means in the management of patients with HSV-1 ocular infection.